ClinicalTrials.gg
RecruitingNCT07088757Updated Nov 18, 2025

Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis

A Phase 4 interventional study of standard dose indomethacin and low dose indomethacin in Post-ERCP Pancreatitis, sponsored by Changhai Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Changhai Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing indomethacin in Pancreatitis — 6 open to participants now, 6 under way, 1 of them phase 3. Indomethacin · Pancreatitis.

Planned enrollment
6th of 20
1,366 · median 492
Started
2025
with 1 other
Phase 4
7 of 20
3 open now
Registered
18th of 20
by date
Lead sponsor
2 of 20
Changhai Hospital

Among the 20 studies testing indomethacin in Pancreatitis, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 18th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

6 of the 20 studies testing indomethacin in Pancreatitis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About indomethacin

Indomethacin: first FDA approval 1965 (INDOCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing indomethacin in Pancreatitis, or all of them as a file.
02

Study summary

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a widely used procedure for diagnosing and treating pancreatic and biliary diseases. Despite its benefits, ERCP carries a risk of post-procedure pancreatitis (PEP), which occurs in approximately 12.2% of cases and can significantly increase healthcare costs and patient morbidity. Preventing PEP is crucial for improving patient outcomes and reducing the economic burden of ERCP.

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as indomethacin, have been shown to be effective in reducing the incidence of PEP when administered rectally before ERCP. The standard dose recommended by guidelines is 100mg, which has been associated with a significant reduction in PEP rates. However, higher doses of NSAIDs can increase the risk of adverse events, including gastrointestinal bleeding and renal impairment. Therefore, there is a need to determine whether a lower dose can provide similar benefits without increasing these risks.

This multicenter, non-inferiority, double-blind, randomized controlled trial will be conducted in China. Participants will be adults aged 18 or older scheduled for ERCP. They will be randomly assigned in a 1:1 ratio to either the low-dose (50mg) or standard-dose (100mg) indomethacin group. The intervention will be administered rectally 30 minutes before the ERCP procedure. The study will follow a double-blind design, ensuring that both patients and investigators are unaware of the treatment allocation.

The results of this trial could significantly influence clinical practice by providing evidence on the effectiveness of a lower dose of indomethacin in preventing PEP. This could lead to a reduction in the risk of adverse events associated with higher doses and potentially decrease healthcare costs without compromising patient safety. By optimizing the dosing of indomethacin, this study aims to improve the safety and cost-effectiveness of ERCP procedures.

03

Conditions studied

  • Post-ERCP Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Patients planned to undergo Endoscopic Retrograde Cholangiopancreatography

Exclusion criteria

Exclusion Criteria:

  • Standard to ERCP
  • Allergy to Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Use of NSAIDs within 7 days prior to ERCP
  • Not suitable for NSAIDs administration (gastrointestinal hemorrhage within 4 weeks, renal dysfunction [Cr >1.4mg/dl=120umol/l]; presence of coagulopathy before the procedure)
  • Acute pancreatitis within 3 days before ERCP
  • Hemodynamic instability
  • Pregnancy or lactation
  • Patients who are unwilling or unable to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,366 participants (estimated)

Study arms

  • Experimental
    low dose indomethacin

    patients randomized to this intervention receive 50mg indomethacin

    Drug: low dose indomethacin

  • Active comparator
    standard dose indomethacin

    patients randomized to this intervention receive 100mg indomethacin

    Drug: standard dose indomethacin

Interventions

  • DrugIndomethacinStudies of IndomethacinIndomethacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to this intervention receive 100mg indomethacin suppositories within 30 min before ERCP.

  • DrugIndomethacinStudies of IndomethacinIndomethacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients randomized to this intervention receive 50mg indomethacin suppositories within 30 min before ERCP.

06

What researchers measure

Primary outcomes

  1. The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis

    Time frame: Within 48 hours after ERCP

Secondary outcomes

  1. The Proportion of Subjects in Each Study Group With Moderate-severe Post-ERCP Pancreatitis

    Time frame: Within one month of ERCP

  2. Rate of Overall ERCP-related complications

    ERCP-related complications include post-ERCP pancreatitis, gastrointestinal bleeding, perforation or infection according to Cotton Criteria.

    Time frame: Within one month of ERCP

  3. Rate of ERCP-related perforation

    Time frame: Within one month of ERCP

  4. Rate of ERCP-related infection

    Time frame: Within one month of ERCP

  5. Rate of ERCP-related bleeding

    Time frame: Within one month of ERCP

  6. Rate of NSAIDs-related complications

    NSAIDs-related complications include: acute kidney injury, allergic reaction, gastrointestinal bleeding, myocardial infarction, cerebrovascular accident, and death

    Time frame: Within one month of ERCP

07

Study locations

3 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2025
First posted
Jul 28, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07088757
Lead sponsor
Changhai Hospital
Collaborators
Sir Run Run Shaw Hospital, Ruijin Hospital, Shanghai General Hospital, China, Jinhua Central Hospital, Taizhou Enze Medical Center Group, Dongyang People's Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Ningbo University, Affiliated Hospital of Jiaxing University, People's Hospital of Quzhou, Zhuji People's Hospital of Zhejiang Province
Responsible party
Zhaoshen Li (Professor, Changhai Hospital) — Principal investigator
First posted
Jul 28, 2025
Start date
Sep 15, 2025
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 18, 2025

Study contacts

Liang-Hao Hu
Contact
lianghao-hu@hotmail.com
+8613817593520
Zhao-Shen Li
Contact
zhaoshen-li@hotmail.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indomethacin

Start the discussion